Fundamental Analysis of REVANCE THERAPEUTICS INC(NASDAQ:RVNC) stock

Fundamental Rating

Overall RVNC gets a fundamental rating of 3 out of 10. We evaluated RVNC against 198 industry peers in the Pharmaceuticals industry. RVNC may be in some trouble as it scores bad on both profitability and health. RVNC is valued quite expensively, but it does show have an excellent growth rating.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year RVNC has reported negative net income.

RVNC had a negative operating cash flow in the past year.

RVNC had negative earnings in each of the past 5 years.

RVNC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

RVNC's Return On Assets of -67.72% is on the low side compared to the rest of the industry. RVNC is outperformed by 66.67% of its industry peers.

		Industry Rank	Sector Rank
ROA	-67.72%
ROE	N/A
ROIC	N/A

ROA(3y)-60.64%

ROA(5y)-53.59%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

RVNC has a Gross Margin of 68.23%. This is in the better half of the industry: RVNC outperforms 71.28% of its industry peers.

RVNC's Gross Margin has been stable in the last couple of years.

RVNC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	68.23%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.51%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

RVNC does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, RVNC has more shares outstanding

Compared to 5 years ago, RVNC has more shares outstanding

RVNC has a worse debt/assets ratio than last year.

2.2 Solvency

RVNC has an Altman-Z score of -6.15. This is a bad value and indicates that RVNC is not financially healthy and even has some risk of bankruptcy.

RVNC has a worse Altman-Z score (-6.15) than 66.67% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-6.15

ROIC/WACCN/A

WACC7.03%

2.3 Liquidity

RVNC has a Current Ratio of 3.80. This indicates that RVNC is financially healthy and has no problem in meeting its short term obligations.

RVNC's Current ratio of 3.80 is in line compared to the rest of the industry. RVNC outperforms 55.38% of its industry peers.

A Quick Ratio of 3.29 indicates that RVNC has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 3.29, RVNC is in line with its industry, outperforming 55.38% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.8
Quick Ratio	3.29

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.81% over the past year.

The Revenue has grown by 76.54% in the past year. This is a very strong growth!

The Revenue has been growing by 129.20% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)3.81%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q34.74%

Revenue 1Y (TTM)76.54%

Revenue growth 3Y148.24%

Revenue growth 5Y129.2%

Revenue growth Q2Q39.82%

3.2 Future

RVNC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.44% yearly.

The Revenue is expected to grow by 31.62% on average over the next years. This is a very strong growth

EPS Next Y38.1%

EPS Next 2Y30.97%

EPS Next 3Y26.57%

EPS Next 5Y20.44%

Revenue Next Year24.46%

Revenue Next 2Y30%

Revenue Next 3Y30.77%

Revenue Next 5Y31.62%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

RVNC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVNC. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

RVNC's earnings are expected to grow with 26.57% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y30.97%

EPS Next 3Y26.57%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for RVNC!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

REVANCE THERAPEUTICS INC

NASDAQ:RVNC (4/26/2024, 7:14:30 PM)

After market: 3.4 0 (0%)

3.4

+0.11 (+3.34%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap354.35M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-67.72%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	68.23%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.49

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.8
Quick Ratio	3.29
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)3.81%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y38.1%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)76.54%

Revenue growth 3Y148.24%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

REVANCE THERAPEUTICS INC (RVNC)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens